Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2014. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction and does not contain consolidated financial statements.
Material Changes
The filing details a transaction by Roger Connor, a Person Discharging Managerial Responsibility, on November 6, 2014:
- Exercise of options over 1,100 Ordinary Shares granted on December 2, 2004, at an exercise price of £11.23 per share.
- Immediate sale of the 1,100 Ordinary Shares at a price of £14.14 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of a specific share transaction.
Investor Verification Points
- Verify the total number of shares held by Roger Connor post-transaction to assess ongoing insider exposure.
- Confirm the timing of the option grant (2004) relative to the exercise date to understand the vesting period.
- Review the price differential between the exercise price (£11.23) and sale price (£14.14) to calculate the realized gain on this specific transaction.